New findings on therapeutic hypothermia following cardiac arrest in children

	Tweet

Intravenous delivery of cold fluids to reduce body temperature quickly after a heart attack and improve neurologic outcomes may not be as effective in children as it is in adults, according to a study reported in Therapeutic Hypothermia and Temperature Management, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available free online at http://www.liebertpub.com/ther

In adults, therapeutic hypothermia to minimize neurological complications caused by cardiac arrest can be achieved by rapidly infusing cold (4oC) intravenous fluid. However, this might not be the optimal approach in children. Alexis Topjian, Michael Hamid, Larissa Hutchins, and Vinay Nadkarni, The Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, studied the effect of the infusion rate on the temperature of the cold IV fluid in three simulated pediatric patients of different weights. They describe the study design and their results in the article entitled, “Can a Cold (4oC) IV Fluid Bolus to Induce Therapeutic Hypothermia Really Deliver 4oC to Children?”

“This is an important and timely contribution because it reinforces the point that children are not just small people but require specialized treatment strategies to target pediatric CNS injury,” says Editor-in-Chief W. Dalton Dietrich, PhD, Kinetic Concepts Distinguished Chair in Neurosurgery, Professor of Neurological Surgery, Neurology and Cell Biology and Anatomy, University of Miami Leonard M. Miller School of Medicine.

Therapeutic Hypothermia and Temperature Management is a groundbreaking quarterly publication published in print and online. The Journal provides a strong multidisciplinary forum to explore all aspects of hypothermia including its application in cardiac arrest, spinal cord and traumatic brain injury, stroke, myocardial ischemia, neurogenic fever, emergency medicine, ICU management, anesthesiology, pediatrics, and much more. Novel findings from translational preclinical investigations as well as clinical studies and trials will be featured in original articles, state-of-the-art review articles, provocative roundtable discussions, clinical protocols, and best practices. Complete tables of content and a free sample issue are available online at http://www.liebertpub.com/ther

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Neurotrauma. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available at http://www.liebertpub.com

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101

###

Contact: Vicki Cohn

914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

RELATED STORIES:
Scientists turn skin cells into beating heart muscle   Too many people get angioplasties, study suggests   New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA   Heart Damage After Chemo Linked to Stress in Cardiac Cells   What’s good or bad for the heart, may be the same for the brain   Warfarin in Heart Failure   Increased Sudden Cardiac Death Rate Among HIV Patients   Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease   Lack of basic evidence hampering prevention of sudden heart attacks in sport   Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study   Heart attack patients taken to PCI hospitals first treated faster   Cameron Health’s under-skin ICD safe, effective

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]